| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
1 Gene Therapy Laboratory, Genome Research Center, 2 Department of Biochemistry, University of Hong Kong, Pokfulam, Hong Kong; 3 National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, China; and 4 Department of Haematological and Molecular Medicine, GKT School of Medicine, King's College London, United Kingdom
Requests for reprints: Ruian Xu, Gene Therapy Laboratory, Genome Research Centre, University of Hong Kong, 8S-01, Kadoories BioScience Building, Pokfulam, Hong Kong. Phone: 852-2299-0757; Fax: 852-2817-9488; E-mail: rxua{at}hkucc.hku.hk.
Recombinant adeno-associated virus 2/5 (rAAV2/5), a hybrid rAAV-2 with AAV-5 capsid, seems to be a very efficient delivery vector for the transduction of the lung adenocarcinoma cell line A549. Infection of the A549 cell line with a rAAV2/5 vector encoding the extracellular domain of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, amino acids 114-281) resulted in secretion of soluble TRAIL (sTRAIL) and induction of apoptosis in these cells. rAAV2/5-sTRAIL mediated delivery and stable expression of sTRAIL resulted in the presence of the trimeric form of sTRAIL in sera of nude mice that were implanted with s.c. or orthotopic A549 tumors. The rAAV2/5-sTRAIL transduction of the tumors resulted in a statistically significant reduction in tumor growth and prolonged survival of the tumor-bearing animals. Primary cell culture, histologic examination of the tumors, and serum analyses showed the absence of detectable TRAIL-induced toxicity in normal tissues including the liver. The successful inhibition of lung cancer growth and the absence of detectable toxicity suggest a putative role for rAAV2/5-sTRAIL114-281 in the therapy of lung cancer.
Key Words: TRAIL AAV NSCLC cancer gene therapy apoptosis
This article has been cited by other articles:
![]() |
H. J. Millar, J. A. Nemeth, F. L. McCabe, B. Pikounis, and E. Wickstrom Circulating Human Interleukin-8 as an Indicator of Cancer Progression in a Nude Rat Orthotopic Human Non-Small Cell Lung Carcinoma Model Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2180 - 2187. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Xu, Y.-s. Wang, W.-b. Pan, B. Xiao, Y.-j. Wen, X.-c. Chen, L.-j. Chen, H.-x. Deng, J. You, B. Kan, et al. Human {alpha}-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice Mol. Cancer Ther., June 1, 2008; 7(6): 1588 - 1597. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. X. Cai, L. Y. Tse, C. Leung, P. K.H. Tam, R. Xu, and M. H. Sham Suppression of Lung Tumor Growth and Metastasis in Mice by Adeno-Associated Virus-Mediated Expression of Vasostatin Clin. Cancer Res., February 1, 2008; 14(3): 939 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lin, W. Wei, J. Zhang, S. Liu, Y. Liu, and D. Zheng Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity Mol. Cancer Ther., October 1, 2007; 6(10): 2618 - 2625. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Wohlfahrt, B. C. Beard, A. Lieber, and H.-P. Kiem A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models Cancer Res., September 15, 2007; 67(18): 8783 - 8790. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shi, Y. Liu, Y. Zheng, Y. Guo, J. Zhang, P.-t. Cheung, R. Xu, and D. Zheng Therapeutic Expression of an Anti-Death Receptor 5 Single-Chain Fixed-Variable Region Prevents Tumor Growth in Mice Cancer Res., December 15, 2006; 66(24): 11946 - 11953. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Yang, S.-O Park, A-R. Yoon, J. Y. Yoo, M. K. Kim, C.-O. Yun, and C.-W. Kim Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol. Cancer Ther., June 1, 2006; 5(6): 1610 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
TRAIL Gene Therapy for Lung Cancer Cancer Res., May 1, 2005; 65(9): 3966 - 3966. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |